Experimental KRAS G12D drug slows cancer growth, shrinks tumors in early test

MedicalXpress | mai 02, 2026

A first-in-human clinical trial led by an international team of researchers and published in the New England Journal of Medicine found that setidegrasib, an investigational targeted therapy drug designed to eliminate a key cancer-driving protein called KRAS G12D, shows encouraging early activity in patients with advanced lung and pancreatic cancers.